Skip to content
We are a research and development biopharmaceutical company focused on next generation of targeted cancer therapies. We develop our personalized ADC (Antibody-Drug Conjugate) cancer treatment both independently and through research and development collaborations. Personalized cancer medicine can have fewer side effects than other types of treatment, affecting healthy cells less and cancer cells more. Our fundamental goal is to specifically target the microenvironment of cancer cells for increased efficacy and improved safety and reduced off-target effects. We focus on the preventive treatment of stage 4 of cancer, when cancer cells have spread far from their origin to other organs of the body (progression is also known as metastasis), which usually means that the cancer can no longer be curable by local therapies such as surgery or radiotherapy.
